Pharmaceutical Pricing Strategies: Optimizing returns throughout R&D and marketing

Executive Summary

Pricing regulations and reimbursement trends are continually changing in response to ever increasing cost containment pressures; impending Medicare reform in the US, continued price cuts in Japan and increasing reference pricing and parallel trade throughout Europe are likely to lead to continued downward pressure on global pharmaceutical prices. At the same time, pharmaceutical earnings are being squeezed by heightened competition and flagging R&D productivity levels. The new management report Pharmaceutical Pricing Strategies: Optimizing returns throughout R&D and marketing, examines global pricing of pharmaceutical and biotechnology products and maps out the future scenarios affecting companies. This report provides a framework for devising an optimal pricing strategy in order to maximize the returns from new and established products. Pharmaceutical Pricing Strategies: Optimizing returns throughout R&D and marketing, examines current and future pricing and reimbursement trends in the US, Japanese and major European pharmaceutical markets. This report evaluates potential strategies whereby both your R&D and sales and marketing functions can support the pricing function in achieving optimal product returns. Find out whether your predictions of trends in pharmaceutical pricing are consistent with key industry analysts’ and determine how your company will deal with the impact of these trends, with the help of this new report.